Comparative Pharmacology
Head-to-head clinical analysis: RESPORAL versus SEFFIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RESPORAL versus SEFFIN.
RESPORAL vs SEFFIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
RESPORAL contains theophylline, a methylxanthine that inhibits phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cAMP and cGMP levels. It also antagonizes adenosine receptors, resulting in bronchodilation and anti-inflammatory effects.
SEFFIN is a brand name for cefazolin, a first-generation cephalosporin antibiotic. It inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It is bactericidal against susceptible organisms.
2 mg orally twice daily
1-2 g IV/IM every 6-8 hours; maximum 8 g/day.
None Documented
None Documented
Terminal half-life is 12 hours (range 10-14 h), supporting twice-daily dosing in most patients.
Terminal elimination half-life is approximately 0.5-1 hour in adults with normal renal function; prolonged to 20-40 hours in severe renal impairment (CrCl <10 mL/min).
Renal excretion accounts for 70% of elimination (30% unchanged), biliary/fecal 20%, and 10% metabolized.
Primarily renal (80-90% unchanged) via glomerular filtration and tubular secretion; minor biliary excretion (<5%) and fecal elimination.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic